NewAmsterdam Pharma Co N.V.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
Netherlands
Business Address
GOOIMEER 2-35, NARRDEN, P7, 1411 DC
Mailing Address
GOOIMEER 2-35, NARRDEN, P7, 1411 DC
Phone
35 206 2971
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
$864.62M
Total Assets
$-2.15
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | March 12, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | March 9, 2026 | View on SEC |
| 4 Insider stock transaction report | March 2, 2026 | View on SEC |
| 8-K Current report of material events | March 2, 2026 | View on SEC |
| 4 Insider stock transaction report | February 26, 2026 | View on SEC |
| 4 Insider stock transaction report | February 24, 2026 | View on SEC |
| 8-K Current report of material events | February 18, 2026 | View on SEC |
| 10-K Annual financial report | February 18, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
Annual Reports
10-K
February 18, 2026
- Lead drug candidate, obicetrapib, is advancing through pivotal Phase 3 clinical trials for cardiovascular and metabolic diseases.
- Company maintains a strong cash position of $350 million, providing a projected cash runway into late 2027.
Insider Trading
STRONG SELL
5 insiders
34 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.